Posters & Publications
The following information is from select congresses and is not intended to be a complete overview of all congresses, congress materials and clinical information. These materials may include information for products that are not approved and/or information that is inconsistent with product uses as described in the Prescribing Information (PI). BioXcel Therapeutics does not suggest or recommend the use of products in any manner other than as described in the PI.
Clinical/Pre-Clinical
- Agitation Associated with Schizophrenia or Bipolar Disorder: Sublingual Dexmedetomidine Film Efficacy by Baseline Agitation Level: Psych Congress 2023
- Dexmedetomidine Sublingual Film for the Treatment of Acute Agitation Associated with Schizophrenia or Bipolar Disorder: Effect Size and Pooled Efficacy: AAPP 2023 ENCORE
- Number Needed to Treat (NNT) and Number Needed to Harm (NNH) from Two Phase 3 Studies of Sublingual Dexmedetomidine for Treating Acute Agitation in Patients with Schizophrenia and Bipolar Disorder: NEI 2022
- Sublingual Dexmedetomidine for the Treatment of Acute Agitation Associated with Schizophrenia or Bipolar Disorder: Effect Size and Pooled Efficacy: ACLP 2022
- Dexmedetomidine Sublingual Film for Treatment of Acute Agitation Associated With Schizophrenia or Bipolar Disorder: SERENITY I and SERENITY II Trials: APNA 2022
- Number Needed to Treat (NNT) and Number Needed to Harm (NNH) from Two Phase 3 Studies of Sublingual Dexmedetomidine for Treating Acute Agitation in Patients with Schizophrenia and Bipolar Disorder: PsychCongress 2022
- Sublingual Dexmedetomidine Demonstrates Significant Reduction in Agitation Across Baseline Severity in Patients With Bipolar Disorders: ISBD 2022
- Dexmedetomidine Sublingual Film for Acute Agitation Associated With Schizophrenia or Bipolar Disorder: Pooled Clinical Trial Data: SAEM 2022
- Dexmedetomidine Sublingual Film: Post Hoc Analysis of PANSS-Excited Component Items in Acute Agitation Associated With Schizophrenia or Bipolar Disorder: APA 2022
- Safety, Acceptability, and Pharmacokinetics of Dexmedetomidine Orally Dissolving Film (BXCL501) for Treating Acute Agitation in Patients with Schizophrenia: ASHP 2021
- Dexmedetomidine Orally Dissolving Film (BXCL501) for the Treatment of Acute Agitation Associated With Schizophrenia or Bipolar Disorder: SERENITY I and SERENITY II Clinical Trials: PsychCongress 2021
- BXCL501 Demonstrates Significant Reduction in Agitation Across all Mood States (Depressed, Hypomanic, Manic) in Patients With Bipolar Disorder: ISBD 2021
- Effect of BXCL501 for Treating Acute Agitation in Patients with Bipolar Disorder: ISBD 2021
- Pharmacokinetics of Dexmedetomidine after a Single Sublingual Dose of BXCL501 in Patients with Agitation Associated with Schizophrenia: ISBD 2021
- Safety and Patient Acceptability of BXCL501 for Treating Acute Agitation in Patients with Bipolar Disorder: ISBD 2021
- A Novel Rapidly Effective Treatment of Agitation for Schizophrenia with the Oral Dissolving Film BXCL501: APA 2021
- Novel Rapidly Effective Treatment of Agitation in Patients with Bipolar Disorders: BXCL501 – An Oral Dissolving Film: APA 2021
Health Outcomes / Real-World Experience
- Treatment and Economic Challenges when Treating Patients with Agitation Associated with Schizophrenia or Bipolar Disorder in the Emergency Department: AAEP NUBE 2023
- Real-world Pilot Survey of Clinical Experience Using Dexmedetomidine Sublingual Film for Acute Agitation in Adults with Schizophrenia or Bipolar Disorder: CSHP 2023
- Direct Medical Cost-Estimator Tool – Economic Burden of Physically Restrained Patients with Agitation and Bipolar Disorder in Emergency Departments: ISBD 2023
- Clinical Characteristics of Patients with Agitation Episodes Associated with Bipolar Disorder or Schizophrenia –Real World Patient Journey: ISPOR 2023
- Real World Impact of Patients with Bipolar Disorder or Schizophrenia who Experience High Frequency (HF) of Agitation Episodes: AMCP 2023
- Clinical Management of Acute Agitation in Patients with Schizophrenia or Bipolar Disorder in Emergency Departments in the United States –A Retrospective Chart Review: ASHP 2022
- Characterization of Patients With Acute Agitation and Schizophrenia Treated in Emergency Departments in the United States: A Retrospective Chart Review: AMCP 2022
- Direct Medical Cost-Estimator Tool –Economic Burden of Physically Restraining Patients with Agitation and Schizophrenia in Emergency Departments: ISPOR 2022
- Characterization and Charges of Emergency Department Encounters and Restraints in Patients with Acute Agitation and Schizophrenia or Bipolar Disorder Using Nationwide Emergency Department Sample Data: ASHP 2021
- Estimating the Prevalence of Acute Agitation Associated with Schizophrenia and Bipolar Disorder Resulting in Emergency Department Visits in the US: AMCP 2021
- Number Needed to Treat and Number Needed to Harm From Two Phase 3 Studies of Dexmedetomidine Orally Dissolving Film (BXCL501) for Treating Acute Agitation in Patients With Schizophrenia and Bipolar Disorder: AMCP 2021
- Epidemiology of Acute Agitation Secondary to Schizophrenia and/or Bipolar Disorder in Patients Presenting to Emergency Departments: A Systematic Literature Review: ISPOR 2021
